BioMedNewsBreaks

MondayMar 23, 2026 2:58 pm

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Advances Orphan Drug Strategy With HyBryte In Rare Skin Cancer

Soligenix (NASDAQ: SNGX) is advancing a differentiated approach to orphan drug development, emphasizing a de-risked model focused on patient safety and capital efficiency, as highlighted in a recent citybiz feature. The company’s lead candidate, HyBryte(TM), targets cutaneous T-cell lymphoma using visible light activation rather than traditional chemotherapy or UV-based therapies, with clinical data indicating faster response times and a favorable safety profile, while also supporting potential at-home treatment through telehealth-enabled delivery. The company is nearing completion of a confirmatory Phase 3 study for HyBryte(TM), with interim analysis expected in early 2026 and top-line results later in the year, alongside supportive data showing strong patient response rates. Soligenix’s broader strategy leverages regulatory incentives for…

Continue Reading

MondayMar 23, 2026 10:59 am

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) HyBryte Data To Be Presented At USCLC Workshop Ahead Of AAD Meeting 

Soligenix (NASDAQ: SNGX) announced that new supportive trial data for HyBryte(TM) in the treatment of cutaneous T-cell lymphoma will be presented at the United States Cutaneous Lymphoma Consortium Workshop on March 26, 2026, ahead of the American Academy of Dermatology Annual Meeting. The presentations will highlight positive results from a long-term treatment study and a comparative analysis versus Valchlor(R), supporting HyBryte(TM) potential as a therapeutic option for CTCL. To view the full press release, visit https://ibn.fm/iTepg About Soligenix Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Our Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte(TM) (SGX301…

Continue Reading

MondayMar 23, 2026 9:40 am

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Subsidiary Sapu Nano To Present Everolimus Toxicology Data At SOT 2026

Oncotelic Therapeutics (OTCQB: OTLC) announced that its subsidiary Sapu Nano will present new data on everolimus toxicology at the Society of Toxicology 2026 Annual Meeting and ToxExpo in San Diego, highlighting findings on tissue concentration–driven effects and organ-specific outcomes beyond traditional plasma pharmacokinetics. The presentation underscores the importance of tissue-level drug distribution in determining toxicity profiles and supports the development of improved delivery strategies, including intravenous and nanoparticle-based formulations. To view the full press release, visit https://ibn.fm/kZzE3 About Sapu Nano Sapu Nano is a biotechnology company developing next-generation nanomedicine platforms to improve drug delivery, enhance therapeutic index, and unlock new clinical…

Continue Reading

FridayMar 20, 2026 1:17 pm

BioMedNewsBreaks — Co-Diagnostics, Inc. (NASDAQ: CODX) Expands CoSara Distribution Territory Across South Asia 

Co-Diagnostics (NASDAQ: CODX) announced that its Indian joint venture, CoSara Diagnostics Pvt. Ltd., has signed an agreement to expand its commercial and distribution territory across South Asia to include Bangladesh, Pakistan, Nepal and Sri Lanka, significantly increasing its addressable market to an estimated $13.0 billion. The expansion supports planned commercialization of the CoSara PCR Pro(R) point-of-care platform and SARAGENE(R) product line, subject to regulatory approvals, as the company builds regional distribution channels and positions for broader deployment of its molecular diagnostics solutions. To view the full press release, visit https://ibn.fm/wgvJ8 About Co-Diagnostics, Inc. Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies…

Continue Reading

FridayMar 20, 2026 10:00 am

BioMedNewsBreaks — Black Hawk Acquisition Corporation (Nasdaq: BKHA) SPAC Target Vesicor Therapeutics Names Michael Tolentino CEO

Black Hawk Acquisition (Nasdaq: BKHA, BKHAU, BKHAR) announced that its proposed de-SPAC acquisition target, Vesicor Therapeutics Inc., has appointed Michael Tolentino, M.D., as chief executive officer effective March 17, 2026, succeeding founder Luo Feng, Ph.D., who will transition to chief scientific officer as the company advances its p53-based cancer therapeutic platform and prepares for IND-enabling studies and a planned FDA submission. Dr. Tolentino brings more than 20 years of biotechnology leadership experience spanning drug discovery, clinical development and company building, including roles in the development of Avastin and leadership positions at multiple biotech firms, and is expected to support execution of Vesicor growth strategy and progression toward…

Continue Reading

ThursdayMar 19, 2026 10:45 am

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Highlights HyBryte Clinical Data In Peer-Reviewed Journal Publication

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on rare diseases, announced that a comprehensive summary of clinical trials evaluating HyBryte(TM) (synthetic hypericin) for cutaneous T-cell lymphoma has been published in the peer-reviewed journal Expert Opinion on Investigational Drugs, highlighting the therapy’s safety profile, non-mutagenic mechanism and demonstrated efficacy across studies, while supporting its potential as a first-line treatment option as the company advances its ongoing FLASH2 Phase 3 trial with interim analysis expected in the second quarter of 2026. To view the full press release, visit https://ibn.fm/9E41P About Soligenix Inc. Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is…

Continue Reading

ThursdayMar 19, 2026 10:32 am

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Featured On BioMedWire Podcast Highlighting Phase 3 HyBryte Progress And Key Inflection Points

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on rare diseases, was featured in the latest BioMedWire Podcast episode where CEO Christopher Schaber discussed the upcoming interim analysis of the Phase 3 FLASH2 study evaluating HyBryte(TM) for cutaneous T-cell lymphoma, noting strong blinded aggregate response rates above initial assumptions and outlining potential outcomes including early study completion or continued enrollment, while emphasizing upcoming interim and top-line data as potentially transformational milestones supporting commercialization and partnership opportunities.  To view the full press release, visit https://ibn.fm/wYVlS About Soligenix Inc. Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.…

Continue Reading

ThursdayMar 19, 2026 9:50 am

BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Partners With NeuroRPM To Integrate AI Platform In Parkinson Study

Annovis Bio (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company, announced a partnership with NeuroRPM to implement an FDA-cleared AI platform in its ongoing Parkinson’s disease study, enabling real-time monitoring of symptoms such as bradykinesia, tremor and dyskinesia through wearable and mobile technology, with the data serving as digital biomarkers to enhance disease tracking, support evaluation of buntanetap over the 36-month trial and provide deeper insights into treatment response and future clinical development. To view the full press release, visit https://ibn.fm/iqVYf About Annovis Headquartered in Malvern, Pennsylvania, Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company developing…

Continue Reading

WednesdayMar 18, 2026 10:50 am

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Secures Costa Rica Approval for Kinesiology Tape Line 

Nutriband (NASDAQ: NTRB) announced that the Costa Rica Ministry of Health has approved its line of kinesiology tapes for import and sale, with exclusive distribution partner Innomedica CCB overseeing and financing the regulatory process. The company plans to ramp up marketing efforts in partnership with Innomedica, targeting both its kinesiology tape products and mosquito repellent patch line following the approval. To view the full press release, visit https://ibn.fm/LmF4t About Nutriband Inc. We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA(TM) abuse-deterrent technology. AVERSA(TM) technology can be incorporated into any transdermal…

Continue Reading

TuesdayMar 17, 2026 11:44 am

BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Receives FDA Feedback On Bioequivalence For Ketamine Product 

NRx Pharmaceuticals (NASDAQ: NRXP) announced it received a letter from the FDA’s Bioequivalence Program stating no bioequivalence deficiencies were identified at this time in its Abbreviated New Drug Application, with a preliminary determination ahead of anticipated approval in Summer 2026. The company highlighted its preservative-free ketamine formulation, which excludes benzethonium chloride, as a potential advancement in safety and stability, while continuing to pursue regulatory pathways for broader therapeutic use. To view the full press release, visit https://ibn.fm/fNDMM About NRx Pharmaceuticals, Inc. NRx Pharmaceuticals, Inc. (www.nrxpharma.com), is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic…

Continue Reading